

# FLUVASTATIN

---

## Products Affected

### Step 2:

- fluvastatin 20 mg capsule
- fluvastatin 40 mg capsule
- fluvastatin ER 80 mg tablet, extended release 24 hr

## Details

---

<b>Criteria</b>	For new starts only, claims for fluvastatin will process if a claim for simvastatin, atorvastatin, or rosuvastatin is processed in the past 120 days.
-----------------	---

---

## GLP-1 AGONISTS

---

### Products Affected

#### Step 2:

- Bydureon 2 mg/0.65 mL subcutaneous pen injector
- Bydureon BCise 2 mg/0.85 mL subcutaneous auto-injector
- Byetta 10 mcg/dose(250 mcg/mL)2.4 mL subcutaneous pen injector
- Byetta 5 mcg/dose (250 mcg/mL)1.2 mL subcutaneous pen injector
- Trulicity 0.75 mg/0.5 mL subcutaneous pen injector
- Trulicity 1.5 mg/0.5 mL subcutaneous pen injector
- Trulicity 3 mg/0.5 mL subcutaneous pen injector
- Trulicity 4.5 mg/0.5 mL subcutaneous pen injector
- Victoza 2-Pak 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous pen injector
- Victoza 3-Pak 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous pen injector

### Details

---

<b>Criteria</b>	Under CMS Review.
-----------------	-------------------

---

# MYRBETRIQ

---

## Products Affected

### Step 2:

- Myrbetriq 25 mg tablet,extended release
- Myrbetriq 50 mg tablet,extended release

## Details

---

Criteria
For new starts only, claims will process for Myrbetriq if a claim for oxybutynin, tolterodine, or trospium has been processed in the past 120 days.

## SEMAGLUTIDE

---

### Products Affected

#### Step 2:

- Ozempic 0.25 mg or 0.5 mg (2 mg/1.5 mL) subcutaneous pen injector
- Ozempic 1 mg/dose (2 mg/1.5 mL) subcutaneous pen injector
- Rybelsus 14 mg tablet
- Rybelsus 3 mg tablet
- Rybelsus 7 mg tablet

### Details

<b>Criteria</b>	For new starts only, claims will process for Ozempic or Rybelsus if a claim for metformin has been processed in the past 120 days. Patients with Type 2 diabetes and established ASCVD or indicators of high ASCVD risk are exempt from this metformin Step Therapy.
-----------------	--

# **TYMLOS**

---

## **Products Affected**

### **Step 2:**

- Tymlos 80 mcg/dose (3,120 mcg/1.56 mL)  
subcutaneous pen injector

## **Details**

---

<b>Criteria</b>	FOR NEW STARTS ONLY, CLAIMS FOR TYMLOS WILL PROCESS IF A CLAIM FOR ALENDRONATE, RISEDRONATE, OR IBANDRONATE ARE PROCESSED IN THE PAST 120 DAYS.
-----------------	---

---

# ULORIC

---

## Products Affected

### Step 2:

- febuxostat 40 mg tablet
- febuxostat 80 mg tablet

## Details

<b>Criteria</b>	FOR NEW STARTS ONLY, CLAIMS FOR FEBUXOSTAT WILL PROCESS IF A CLAIM FOR ALLOPURINOL 300 MG PER DAY IS PROCESSED IN THE PAST 120 DAYS.
-----------------	--

**Index**

**B**

Bydureon 2 mg/0.65 mL subcutaneous pen injector ..... 2  
 Bydureon BCise 2 mg/0.85 mL subcutaneous auto-injector..... 2  
 Byetta 10 mcg/dose(250 mcg/mL)2.4 mL subcutaneous pen injector ..... 2  
 Byetta 5 mcg/dose (250 mcg/mL)1.2 mL subcutaneous pen injector ..... 2

**F**

febuxostat 40 mg tablet..... 6  
 febuxostat 80 mg tablet..... 6  
 fluvastatin 20 mg capsule..... 1  
 fluvastatin 40 mg capsule..... 1  
 fluvastatin ER 80 mg tablet,extended release 24 hr ..... 1

**M**

Myrbetriq 25 mg tablet,extended release.... 3  
 Myrbetriq 50 mg tablet,extended release.... 3

**O**

Ozempic 0.25 mg or 0.5 mg (2 mg/1.5 mL) subcutaneous pen injector ..... 4

Ozempic 1 mg/dose (2 mg/1.5 mL) subcutaneous pen injector ..... 4

**R**

Rybelsus 14 mg tablet..... 4  
 Rybelsus 3 mg tablet..... 4  
 Rybelsus 7 mg tablet..... 4

**T**

Trulicity 0.75 mg/0.5 mL subcutaneous pen injector ..... 2  
 Trulicity 1.5 mg/0.5 mL subcutaneous pen injector ..... 2  
 Trulicity 3 mg/0.5 mL subcutaneous pen injector ..... 2  
 Trulicity 4.5 mg/0.5 mL subcutaneous pen injector ..... 2  
 Tymlos 80 mcg/dose (3,120 mcg/1.56 mL) subcutaneous pen injector ..... 5

**V**

Victoza 2-Pak 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous pen injector ..... 2  
 Victoza 3-Pak 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous pen injector ..... 2